Leerink Partnrs Decreases Earnings Estimates for NeoGenomics

NeoGenomics, Inc. (NASDAQ:NEO - Free Report) - Analysts at Leerink Partnrs lowered their Q2 2025 earnings estimates for NeoGenomics in a research note issued on Monday, July 21st. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings of ($0.07) per share for the quarter, down from their previous forecast of ($0.06). Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for NeoGenomics' current full-year earnings is ($0.20) per share. Leerink Partnrs also issued estimates for NeoGenomics' Q3 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.22) EPS, Q1 2026 earnings at ($0.04) EPS, Q2 2026 earnings at $0.00 EPS, Q3 2026 earnings at $0.01 EPS and Q4 2026 earnings at $0.01 EPS.

NEO has been the subject of a number of other reports. Needham & Company LLC decreased their price target on NeoGenomics from $18.00 to $8.50 and set a "buy" rating for the company in a research note on Tuesday, April 29th. The Goldman Sachs Group reduced their target price on shares of NeoGenomics from $15.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. Guggenheim assumed coverage on NeoGenomics in a report on Thursday, May 15th. They issued a "neutral" rating for the company. Wall Street Zen raised NeoGenomics from a "sell" rating to a "hold" rating in a research note on Tuesday, May 13th. Finally, Piper Sandler set a $12.00 target price on NeoGenomics and gave the company an "overweight" rating in a research report on Tuesday, May 6th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $13.83.

NeoGenomics Stock Performance

Shares of NASDAQ NEO opened at $6.42 on Wednesday. The stock has a market cap of $826.25 million, a PE ratio of -10.52 and a beta of 1.63. NeoGenomics has a 1 year low of $6.08 and a 1 year high of $19.12. The firm has a fifty day moving average price of $7.39 and a 200-day moving average price of $9.95. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.05 and a quick ratio of 1.95.

NeoGenomics (NASDAQ:NEO - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The medical research company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.06). NeoGenomics had a negative net margin of 11.54% and a negative return on equity of 2.21%. The firm had revenue of $168.04 million for the quarter, compared to analysts' expectations of $171.38 million. During the same period in the prior year, the business posted ($0.02) EPS. The business's quarterly revenue was up 7.6% compared to the same quarter last year.

Insider Buying and Selling

In other news, CFO Jeffrey Scott Sherman bought 20,000 shares of NeoGenomics stock in a transaction that occurred on Friday, May 2nd. The shares were purchased at an average price of $7.51 per share, for a total transaction of $150,200.00. Following the completion of the acquisition, the chief financial officer owned 158,494 shares of the company's stock, valued at $1,190,289.94. The trade was a 14.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lynn A. Tetrault bought 7,000 shares of the firm's stock in a transaction dated Friday, May 9th. The shares were purchased at an average price of $8.14 per share, with a total value of $56,980.00. Following the acquisition, the director directly owned 7,000 shares in the company, valued at approximately $56,980. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 70,600 shares of company stock valued at $550,438. Company insiders own 2.40% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in NEO. State of Alaska Department of Revenue grew its position in shares of NeoGenomics by 7.7% in the 2nd quarter. State of Alaska Department of Revenue now owns 76,565 shares of the medical research company's stock worth $558,000 after acquiring an additional 5,441 shares in the last quarter. Moody National Bank Trust Division boosted its holdings in shares of NeoGenomics by 4.6% during the second quarter. Moody National Bank Trust Division now owns 89,249 shares of the medical research company's stock valued at $652,000 after acquiring an additional 3,902 shares during the period. Silverberg Bernstein Capital Management LLC grew its position in NeoGenomics by 91.6% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 40,380 shares of the medical research company's stock worth $295,000 after purchasing an additional 19,300 shares during the last quarter. Inspire Investing LLC increased its position in NeoGenomics by 52.3% in the 1st quarter. Inspire Investing LLC now owns 36,760 shares of the medical research company's stock valued at $349,000 after acquiring an additional 12,617 shares during the period. Finally, Intech Investment Management LLC raised its stake in shares of NeoGenomics by 19.7% during the first quarter. Intech Investment Management LLC now owns 151,806 shares of the medical research company's stock valued at $1,441,000 after purchasing an additional 24,965 shares in the last quarter. 98.50% of the stock is owned by institutional investors and hedge funds.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.